SCHEMBL4586323

SCHEMBL4586323

CC(C)OC(=O)c1nc(-c2ccc(=O)[nH]c2)c(-c2ccccc2)nc1N

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATR Q13535 2/20 0.44
PDCD1 Q15116 1/20 0.43
CD274 Q9NZQ7 1/20 0.43
NPSR1 Q6W5P4 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
TP53 P04637 1/20 0.41
ADORA2A P29274 9/20 0.40
MAPK1 P28482 1/20 0.40
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP1A2 P05177 1/20 0.39
MAPT P10636 1/20 0.39
CYP2C9 P11712 1/20 0.39
HPGD P15428 1/20 0.39
CYP2C19 P33261 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
ATM Q13315 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4583299 0.84 ATR (0.47) ATRADORA2AMAPK1KDM4EALDH1A1
SCHEMBL4584311 0.84 ALDH1A1 (0.48) ATRNPSR1SMN1; SMN2TP53MAPK1
SCHEMBL4585033 0.83 ATR (0.46) ATRADORA2AMAPK1KDM4EALDH1A1
SCHEMBL4583921 0.71 USP8 (0.50) ATRADORA2AKDM4EALDH1A1CYP1A2
SCHEMBL4585332 0.68 ADORA2A (0.48) SMN1; SMN2TP53ADORA2AMAPK1KDM4E
SCHEMBL5703293 0.68 PLAU (0.40) ADORA2AMAPK1KDM4EALDH1A1CYP1A2
SCHEMBL3866288 0.68 PLAU (0.59) SMN1; SMN2ADORA2AMAPK1KDM4ENPC1
SCHEMBL4584817 0.66 ADORA2A (0.51) ATRADORA2APLAU
SCHEMBL4583664 0.66 ADORA2A (0.42) ATRADORA2AMAPK1PLAU
SCHEMBL10745547 0.66 CA12 (0.55) PDCD1CD274SMN1; SMN2MAPK1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7407961-B2 Pyrazine derivatives and pharmaceutical use thereof ASTELLAS PHARMA INC. (JP) 2008-08-05 US disclosed
US-20050113387-A1 Pyrazine derivatives and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113387-A1 Pyrazine derivatives and pharmaceutical use thereof ADORA2A, P2RX5, ADORA1 ATR 3727/4885PDCD1 675/4885CD274 1334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.